US-based biotechnology firm FluidForm Bio has made an development in 3D-printing human cardiac tissue utilizing freeform reversible embedding of suspended hydrogels (FRESH) 3D bioprinting, as detailed in a analysis paper revealed in APL Bioengineering.
The analysis paper, titled ‘FRESH 3D-bioprinted cardiac tissue’, a bioengineered platform for in vitro pharmacology, highlights how FluidForm has used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to create an correct mannequin for human cardiac physiology in drug growth. The examine was performed in collaboration with scientists at FluidForm and Merck (MSD).
FRESH makes use of an embedded printing strategy with a brief help gel that makes it potential to 3D print advanced scaffolds utilizing collagen in its native unmodified kind.
Within the announcement accompanying the breakthrough, FluidForm CTO and co-founder Adam Feinberg mentioned: “We’re not conscious of every other biofabrication or tissue engineering approaches that may obtain comparable cell densities and uniaxial alignment available on the market right now, each of which contribute to a extra superior physiologic operate.”
FluidForm Bio was based in 2018, with co-founder Adam Feinberg creating the FRESH printing system in 2015 at Carnegie Mellon College. In 2021, FluidForm entered right into a partnership with J&J’s medical gadget subsidiary Ethicon to develop 3D bioprinting options, utilising FluidForm’s FRESH bioprinting know-how.
In accordance with a GlobalData report, the 3D printing medical market is about to develop within the subsequent few years, from $2bn on the finish of 2022 to greater than $4bn by 2026.
Entry probably the most complete Firm Profiles
available on the market, powered by GlobalData. Save hours of analysis. Achieve aggressive edge.
Firm Profile – free
Your obtain e mail will arrive shortly
We’re assured concerning the
high quality of our Firm Profiles. Nevertheless, we would like you to take advantage of
choice for your corporation, so we provide a free pattern you could obtain by
submitting the beneath kind
There have been many developments within the area of 3D printing this yr, together with the collaboration between CollPlant Biotechnologies and Stratasys to develop 3D-printed breast implants, introduced in April. The businesses will use Stratasys’ P3 technology-based bioprinter and CollPlant’s tobacco plant-based collagen to bio-fabricate human tissues and organs, producing programmes at an industrial scale.
In Might, researchers on the College of Birmingham within the UK developed a path for microfluidic, 3D-bioprinted vessels, tissues, and organs. Microfluidic scaffolds may also help in overcoming the challenges related to 3D cultures, together with price and affordability, that means shorter wait occasions for organ transplantation.